What is it?
Calcitonin gene-related peptide, or CGRP, is a signaling molecule involved in migraine attacks. Newer preventive medicines either bind to CGRP itself or block its receptor.
Why does it matter?
Older migraine preventives were usually borrowed from other areas of medicine. CGRP-targeting treatments were developed specifically around migraine biology.
What did researchers find?
Randomized trials found that several CGRP monoclonal antibodies reduced monthly migraine days for some participants. Individual response differs, and trial averages do not predict exactly how one person will respond.
Where is the science right now?
Multiple injectable antibodies and oral CGRP receptor antagonists have received FDA approval for migraine prevention. Some oral medicines are also approved for acute treatment.
Is this available to patients?
Yes, by prescription in the United States. Insurance criteria, cost, medical history, age, pregnancy considerations, and local approvals affect access.
What are the limitations?
Not everyone responds. Long-term and rare effects take time to characterize, and clinical trials do not include every population or health situation.
What happens next?
Researchers continue to compare treatment sequences, combinations, long-term safety, and predictors of response.
Sources
- U.S. Food and Drug Administration: first CGRP preventive approval
- New England Journal of Medicine: erenumab trial
- American Headache Society: CGRP overview
What This Means
Migraine now has treatment options tied directly to a known biological pathway. That is a meaningful shift, but choosing care still requires an individual clinical conversation.
What We Still Don't Know
Researchers do not yet have a reliable test that predicts which CGRP treatment, if any, will work best for a particular person.